Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials

Fatemeh Zahedipour; Seyede Atefe Hosseini; Mojgan Astaneh; Prashant Kesharwani; Mahmoud Reza Jaafari; Amirhossein Sahebkar

doi:10.1016/j.critrevonc.2023.104032

Application of VEGF/VEGFR peptide vaccines in cancer: A systematic review of clinical trials

Crit Rev Oncol Hematol. 2023 Jul:187:104032. doi: 10.1016/j.critrevonc.2023.104032. Epub 2023 May 20.

Authors

Fatemeh Zahedipour¹, Seyede Atefe Hosseini², Mojgan Astaneh³, Prashant Kesharwani⁴, Mahmoud Reza Jaafari⁵, Amirhossein Sahebkar⁶

Affiliations

¹ Student Research Committee, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran; Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran.
² Department of Medical Biotechnology and Nanotechnology, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran.
³ Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of immunology, School of Medicine, Mazandaran University of Medical Sciences, Sari, Iran.
⁴ Department of Pharmaceutics, School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi 110062, India; Centre for Transdisciplinary Research, Department of Pharmacology, Saveetha Dental College, Saveetha Institute of Medical and Technical Science, Chennai, India.
⁵ Nanotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Department of Pharmaceutical Nanotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran.
⁶ Biotechnology Research Center, Pharmaceutical Technology Institute, Mashhad University of Medical Sciences, Mashhad, Iran; Applied Biomedical Research Center, Mashhad University of Medical Sciences, Mashhad, Iran. Electronic address: amir_saheb2000@yahoo.com.

PMID: 37217108
DOI: 10.1016/j.critrevonc.2023.104032

Abstract

Peptide vaccines that target vascular endothelial growth factor (VEGF) pathway have shown promising results in inducing strong anti-tumor immune responses with minimal toxicity in various clinical studies. This systematic review was conducted to provide a comprehensive evaluation of the therapeutic efficacy, immune response, survival rate, and side effects of VEGF/VEGF receptor-based peptide vaccines. VEGF/VEGFR2 peptide vaccines were found to be safe and effective in inducing anti-tumor immune responses, while induced moderate clinical benefit. In this regard, further clinical trials are necessary to fully evaluate their clinical effects and the exact correlation between induction of immune response and clinical outcomes.

Keywords: Cancer; Immunotherapy; Peptide; Systematic review; VEGF/VEGFR; Vaccine.

Publication types

Systematic Review
Review

MeSH terms

Humans
Neoplasms* / drug therapy
Vaccines, Subunit / therapeutic use
Vascular Endothelial Growth Factor A*
Vascular Endothelial Growth Factor Receptor-2 / metabolism
Vascular Endothelial Growth Factor Receptor-2 / therapeutic use
Vascular Endothelial Growth Factors / therapeutic use

Substances

Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factors
Vascular Endothelial Growth Factor Receptor-2
Vaccines, Subunit